

# Rebecca H Haberman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5803194/publications.pdf>

Version: 2024-02-01

16  
papers

992  
citations

933447

10  
h-index

996975

15  
g-index

19  
all docs

19  
docs citations

19  
times ranked

2254  
citing authors

#	ARTICLE	IF	CITATIONS
1	Covid-19 in Immune-Mediated Inflammatory Diseases – Case Series from New York. New England Journal of Medicine, 2020, 383, 85-88.	27.0	377
2	Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Annals of the Rheumatic Diseases, 2021, 80, 1339-1344.	0.9	202
3	Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following <scp>SARS</scp> – <scp>CoV</scp> – Vaccination. Arthritis and Rheumatology, 2022, 74, 284-294.	5.6	103
4	COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes. Arthritis and Rheumatology, 2020, 72, 1981-1989.	5.6	92
5	Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2020, 72, 1971-1980.	5.6	51
6	Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease. Lancet Rheumatology, The, 2022, 4, e384-e387.	3.9	27
7	Human microbiome, infections, and rheumatic disease. Clinical Rheumatology, 2017, 36, 2645-2653.	2.2	26
8	Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. Nature Reviews Rheumatology, 2021, 17, 238-243.	8.0	23
9	Bridging the Gaps in the Care of Psoriasis and Psoriatic Arthritis: the Role of Combined Clinics. Current Rheumatology Reports, 2018, 20, 76.	4.7	22
10	Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort. Lancet Rheumatology, The, 2021, 3, e585-e594.	3.9	18
11	Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City. Lancet Rheumatology, The, 2022, 4, e582-e585.	3.9	9
12	Induction of remission in biologic-naïve, severe psoriasis and PsA with dual anti-cytokine combination. Rheumatology, 2021, 60, e225-e226.	1.9	7
13	Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting. Journal of Rheumatology, 2021, , jrheum.201671.	2.0	6
14	1206 – Evaluation of SARS-CoV-2 IgG antibody reactivity in a multi-racial/ethnic cohort of patients with systemic lupus erythematosus. , 2021, , .		2
15	COVID-19 outcomes in patients with psoriasis and psoriatic arthritis: A prospective cohort study. JAAD International, 2022, 8, 31-33.	2.2	2
16	Editorial: Rheumatology at the center of coronavirus disease 2019: pathogenesis, treatment, and clinical care. Current Opinion in Rheumatology, 2021, 33, 409-411.	4.3	0